Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 26 clinical trials
Comparing the Consolidation Regimens of IDA With Intermediate-dose Cytarabine Versus Intermediate-dose Cytarabine Alone for Elderly AML Patients

This study evaluates Idarubicin (IDA) in combination with the intermediate-dose cytarabine, compared with intermediate-dose cytarabine alone, as a consolidation treatment for elderly AML in

  • 0 views
  • 23 Jan, 2021
  • 1 location
Treatment Protocol for Non-Metastatic Unilateral Retinoblastoma (RbGALOP2)

This protocol provides guidelines for the management of non-metastatic unilateral retinoblastoma and introduces an innovative adjuvant therapy for higher risk patients based upon the results of the Grupo de America Latina de Oncologia Pediatrica (GALOP) I study. Conservative therapy will be not protocolized.

  • 64 views
  • 01 Mar, 2022
  • 1 location
The Role of Allo-HSCT in MRD-negative Patients With AML Under the Age of 60 Years in the First Complete Remission

Depending on the variant of the disease, patients are divided into 3 groups: A, B and C. Group A include patients with acute myeloid leukemia (AML) inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11, group B - AML with t(8;21)(q22;q22.1); RUNX1-RUNX1T1, AML with normal karyotype with or without gene mutations (FLT3, NPM1, CEBPa) regardless …

  • 0 views
  • 28 Apr, 2022
  • 1 location
Study to Improve OS in 18 to 60 Year-old Patients Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

This open label, multicenter phase II/III study with multiple randomization phases at differents stages of AML treatment (induction, consolidation and HSCT where applicable) is designed to improve OS in younger (18 to 60 year-old) patients, with AML risk-adapted patient strategies. Within the intermediate risk AML group, optimal GvHD prophylaxis following …

idarubicin
consolidation chemotherapies
cytarabine
vosaroxin
methotrexate
  • 42 views
  • 25 Jan, 2021
  • 57 locations
Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)

administration of Bortezomib in patients with B-precursor ALL with initial WBC100,000/l will improve treatment outcome? Whether the administration of Idarubicin instead Daunorubicin in low-risk T-ALL

lymphoid leukemia
daunorubicin
adult t-cell leukemia/lymphoma
b-cell acute lymphoblastic leukemia
dexamethasone
  • 179 views
  • 23 Jan, 2021
  • 59 locations
Safety and Efficacy Study of Idarubicin Dose Intensification to Treat Acute Myeloid Leukemia (IDAML)

The purpose of this study is to determine whether idarubicin dose intensification is safe and effective as a remission induction therapy for acute myeloid leukemia.

idarubicin
secondary acute myeloid leukemia
remission
neoadjuvant therapy
ejection fraction
  • 16 views
  • 02 May, 2022
  • 1 location
2157GCCC:Phase 1 of Calaspargase Pegol-mknl w/ Cytarabine and Idarubicin in Newly Dx AML

Characterizing the regimen limiting toxicity (RLT) of chemotherapeutic drug Calaspargase Pegol-mknl as remission induction and consolidation chemotherapy in patients with newly diagnosed Acute Myeloid Leukemia (AML) and Identifying the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Calaspargase Pegol-mknl.

idarubicin
consolidation chemotherapies
cytarabine
remission
myelodysplastic syndromes
  • 0 views
  • 24 Mar, 2022
Hepatocellular Carcinoma on Cirrhosis With Child A/B7 and Hepatic Intra Arterial Injection of Idarubicin/Lipiodol Emulsion (LIDA-BII)

The investigators propose in this trial to test a hepatic chemotherapy, consisting of the hepatic intra-arterial injection Idarubicin, emulsified with Lipiodol, lipid vector, without

radioembolization
unresectable hepatocellular carcinoma
cirrhosis
neutrophil count
arterial embolization
  • 7 views
  • 16 Feb, 2022
  • 3 locations
Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia

This phase II trial studies how well clofarabine, idarubicin, cytarabine, vincristine sulfate, and dexamethasone work in treating patients with mixed phenotype acute leukemia that is newly

idarubicin
cytarabine
cancer
dexamethasone
rituximab
  • 22 views
  • 04 Oct, 2022
  • 1 location
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

This phase II trial studies how well cladribine, idarubicin, cytarabine, and venetoclax work in patients with acute myeloid leukemia, high-risk myelodysplastic syndrome, or blastic phase chronic

cladribine
idarubicin
hematopoietic growth factors
refractory acute myeloid leukemia (aml)
secondary aml
  • 42 views
  • 17 Mar, 2022
  • 1 location